表紙:トゥレット症候群治療薬開発市場:ステージ別、標的別、作用機序別、投与経路別、分子タイプ別、主要参入企業:2022年
市場調査レポート
商品コード
1063298

トゥレット症候群治療薬開発市場:ステージ別、標的別、作用機序別、投与経路別、分子タイプ別、主要参入企業:2022年

Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

出版日: | 発行: Global Markets Direct | ページ情報: 英文 46 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.31円
トゥレット症候群治療薬開発市場:ステージ別、標的別、作用機序別、投与経路別、分子タイプ別、主要参入企業:2022年
出版日: 2022年02月28日
発行: Global Markets Direct
ページ情報: 英文 46 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要
当レポートでは、トゥレット症候群治療薬開発市場について調査し、トゥレット症候群の概要、開発中の薬剤プロファイル、パイプラインの概要、および市場に参入する企業のプロファイルなどを提供しています。

目次

  • イントロダクション
  • トゥレット症候群-概要
  • トゥレット症候群-治療法の開発
  • パイプラインの概要
  • 企業別パイプライン
  • 大学/機関別パイプライン
  • 企業別開発中の製品
  • 大学/機関別開発中の製品
  • トゥレット症候群-治療評価
  • 標的別評価
  • 作用機序別評価
  • 投与経路別評価
  • 分子タイプ別評価
  • トゥレット症候群-治療法開発に関与する企業
  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • Noema Pharma AG
  • Octapharma AG
  • SOM Biotech SL
  • トゥレット症候群-薬物プロファイル
  • ベバントロール-薬物プロファイル
  • ドロナビノール+パルミドロール-薬物プロファイル
  • 塩酸エコピパム-薬物プロファイル
  • 免疫グロブリン(ヒト)-薬物プロファイル
  • NOE-105-薬物プロファイル
  • セプラノロン-薬物プロファイル
  • 中枢神経系障害およびホルモン障害に対してDRD2に拮抗する小分子-薬物プロファイル
  • トゥレット症候群-休眠プロジェクト
  • トゥレット症候群-製造中止製品
  • トゥレット症候群-製品開発のマイルストーン
  • 注目のニュースとプレスリリース
  • 付録
  • 調査手法
  • 範囲
  • 2次調査
  • 1次調査
  • 専門家委員会の検証
  • お問い合わせ
  • 免責事項
図表

List of Tables

List of Tables

  • Number of Products under Development for Tourette Syndrome, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Tourette Syndrome - Pipeline by Asarina Pharma AB, 2022
  • Tourette Syndrome - Pipeline by Emalex Biosciences Inc, 2022
  • Tourette Syndrome - Pipeline by Evero Health Ltd, 2022
  • Tourette Syndrome - Pipeline by Noema Pharma AG, 2022
  • Tourette Syndrome - Pipeline by Octapharma AG, 2022
  • Tourette Syndrome - Pipeline by SOM Biotech SL, 2022
  • Tourette Syndrome - Dormant Projects, 2022
  • Tourette Syndrome - Discontinued Products, 2022

List of Figures

List of Figures

  • Number of Products under Development for Tourette Syndrome, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products by Targets, 2022
  • Number of Products by Stage and Targets, 2022
  • Number of Products by Mechanism of Actions, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022
目次
Product Code: GMDHC22018IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms, and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tourette Syndrome - Overview
  • Tourette Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tourette Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tourette Syndrome - Companies Involved in Therapeutics Development
  • Asarina Pharma AB
  • Emalex Biosciences Inc
  • Evero Health Ltd
  • Noema Pharma AG
  • Octapharma AG
  • SOM Biotech SL
  • Tourette Syndrome - Drug Profiles
  • bevantolol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • dronabinol + palmidrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ecopipam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • NOE-105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • sepranolone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Tourette Syndrome - Dormant Projects
  • Tourette Syndrome - Discontinued Products
  • Tourette Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Feb 16, 2022: First patient in for landmark Tourette Syndrome study
  • Jan 18, 2022: SciSparc advances its phase IIb clinical trial in patients with Tourette syndrome with its proprietary drug candidate SCI-110
  • Dec 22, 2021: Asarina Pharma receives final approval for landmark phase IIa Tourette study
  • Dec 08, 2021: Noema Pharma hosting key opinion leader webinar on Stuttering
  • Nov 10, 2021: Paragon's portfolio company Emalex Biosciences announces positive topline results from phase 2b clinical study evaluating ecopipam for pediatric Tourette syndrome
  • Sep 16, 2021: Administrative backlog at public authority causes short-term delay in Tourette study
  • Aug 05, 2021: Noema Pharma initiates phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome
  • Jul 26, 2021: SciSparc announces updates regarding its phase IIb study in Tourette Syndrome
  • Jun 22, 2021: Emalex Biosciences announces completion of patient enrollment in phase 2b clinical trial evaluating Ecopipam (EBS-101) for pediatric patients with Tourette Syndrome
  • Jun 08, 2021: Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling
  • May 19, 2021: Asarina Pharma receives approval of CTA for phase IIa Tourette study
  • Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
  • Feb 10, 2021: SciSparc engages Procaps for development and production of CannAmide and its SCI-110 product candidate
  • Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
  • Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer